IL17A and asthma: Interestingly, the majority of people with T2 asthma respond well to standard therapy with inhaled corticosteroids [4], whereas non-T2 (T2 low) asthma is still obscure, is a neutrophilic and paucigranulocytic heterogenous type predominant with adult-onset, is associated with corticosteroid resistance (less responsive), and is inflammation-driven through IL-17, IL-6, and IL-23 with airway smooth muscle or neural dysfunction and may be associated with comorbidities like obesity and gastroesophageal reflux disease [5, 6].